Pharmaceutical Manufacturing and Packaging

The contract entails the commercial-scale manufacture and packaging of 10mg Loratadine tablets in compliance with current Good Manufacturing Practices, with each unit consisting of 500 tablets per blister pack. The effort includes full formulation development and cGMP-compliant production processes to ensure product quality, safety, and consistency, meeting all regulatory standards required for pharmaceutical supply. The work must be performed at the designated place of performance in Fort Stewart, Georgia, with the final product intended for government use under the Department of Defense’s Medical Supply Chain program. The opportunity is structured as a subcontract under NAICS code 325412, with a posted date of April 29, 2026, and a firm response deadline of May 5, 2026. While no specific set-aside designation is provided, the solicitation is issued through the DLA DIBBS system and is open to qualified contractors capable of delivering the finished product in compliance with federal pharmaceutical standards. Successful bidders will be expected to demonstrate proven capability in large-scale tablet manufacturing, packaging integrity, and adherence to the stringent requirements of the Department of Defense’s pharmaceutical procurement protocols.